Nanoleq and Myant share a vision to shift the healthcare paradigm towards prevention, empowering individuals by enabling long-term monitoring through textile computing interfaces and clinical-grade data beyond the hospital setting and into the home. Nanoleq's innovative work in the development of stretchable electrical cables, dry electrodes and biosensing technologies culminated in the flagship Oxa device, which enables users to track their respiratory function, ECG, heart rate variability (HRV), and stress levels through its state-of-the-art sensor system, providing real-time feedback on vital signs to enhance physical and mental well-being.
The company has joined the Myant family, a Toronto-based global innovator in textile-based healthcare, a collaboration that reinforces a shared vision to shift healthcare from reactive treatment to proactive prevention. This acquisition combines Myant’s expertise in AI- driven medical solutions with Nanoleq’s breakthroughs in biosensing and flexible electronics, aiming to deliver continuous, real-time health monitoring—bringing advanced, connected care into everyday life. Through Myant’s “connected skin” technology, Oxa’s capabilities will be scaled further, integrating health insights into clothing that fits seamlessly into daily routines.
“Joining forces with Myant is the ideal path forward for Nanoleq,” said Vincent Martinez, CEO of Nanoleq. “With Myant’s deep expertise in the medical market, we can scale our vision of preventive, everyday healthcare to relevant and valuable applications. Together, we’re building a future where health monitoring is seamlessly woven into daily life, empowering people to take control of their well-being with actionable insights.”
Zurich-based Osmotex to advance its Hydrobot and Steriliser technologies with Myant
Osmotex, which has also been acquired by Myant following a joint venture phase, specializes in the development of Hydrobot and Steriliser technologies that enable precise control of moisture and particles in single microchannels, as well as in membranes and textiles with billions of such channels or pores. For textiles and garments, the technology provides an “electronically controlled breathable membrane” that can match human sweat rates under the most extreme conditions. This innovation is set to be a breakthrough for protective gear and first responder garments by acting as a second skin, enhancing physiological comfort, performance, and safety for the wearer. Following this acquisition, Osmotex fabrics will be deployed in the medical field as a second skin for optimal wound healing and next generation drug delivery systems. Diagnostic applications through fluid sampling, separation and analysis are also being developed.
“With Myant, we are now able to maximize the impact of our technologies,” said Trond Heldal, CEO of Myant Swiss and former CEO of Osmotex. “We developed a unique solid-state pump technology, relying on the most advanced materials science and technology. With Myant, we have an equally unique partner, covering the value chain from their 17,000 square meter state-of-the-art materials laboratories via manufacture to the integration into a wide range of finished products and services.”
Zurich has now been set up as a base for Myant's EU and EMEA expansion. The two acquisitions add valuable talent to the company and enhance its lead in textile technologies. The entry and expansion of Myant into Europe realizes its ambition to become a global leader in healthcare through advanced materials, setting a new standard for how individuals connect with people and technology. Currently, Mayant has invested over $100m in its developing textile computing and advanced materials and secured over 1000 patents for its technologies.
(Press release/RAN)